Drugs / RSV F Vaccine with adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02296463 | Nov 2014 → Sep 2015 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV F Vaccine with adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02296463 ↗ |
| Modality | Vaccine | “Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine” NCT02296463 ↗ |
| Route | Intramuscular | “Treatments will comprise an IM dose of saline placebo or RSV F vaccine on Day 0 and an IM dose of RSV F vaccine or a licensed hepatitis A vaccine on Day 28” NCT02296463 ↗ |